GB0801888D0 - Treatment of mast cell related disorders - Google Patents
Treatment of mast cell related disordersInfo
- Publication number
- GB0801888D0 GB0801888D0 GBGB0801888.9A GB0801888A GB0801888D0 GB 0801888 D0 GB0801888 D0 GB 0801888D0 GB 0801888 A GB0801888 A GB 0801888A GB 0801888 D0 GB0801888 D0 GB 0801888D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- related disorders
- mast cell
- cell related
- mast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0801888.9A GB0801888D0 (en) | 2008-02-01 | 2008-02-01 | Treatment of mast cell related disorders |
PCT/GB2009/050091 WO2009095719A2 (en) | 2008-02-01 | 2009-01-30 | Treatment of mast cell related disorders |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0801888.9A GB0801888D0 (en) | 2008-02-01 | 2008-02-01 | Treatment of mast cell related disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
GB0801888D0 true GB0801888D0 (en) | 2008-03-12 |
Family
ID=39204086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0801888.9A Ceased GB0801888D0 (en) | 2008-02-01 | 2008-02-01 | Treatment of mast cell related disorders |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0801888D0 (en) |
WO (1) | WO2009095719A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008222602B2 (en) | 2007-03-05 | 2013-06-20 | The University Of Queensland | A target for breast cancer therapy and/or diagnosis |
TWI412369B (en) * | 2010-06-07 | 2013-10-21 | Univ Kaohsiung Medical | Pharmaceutical composition for inhibiting cancer cell inflammation |
WO2014153241A1 (en) * | 2013-03-14 | 2014-09-25 | The Regents Of The University Of Michigan | Treatment of staphylococcal disorders |
EP2865758A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene |
US10351624B2 (en) * | 2014-08-07 | 2019-07-16 | Daiichi Sankyo Company, Limited | Anti-Orai1 antibody |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU751139B2 (en) * | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
-
2008
- 2008-02-01 GB GBGB0801888.9A patent/GB0801888D0/en not_active Ceased
-
2009
- 2009-01-30 WO PCT/GB2009/050091 patent/WO2009095719A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2009095719A3 (en) | 2010-05-06 |
WO2009095719A2 (en) | 2009-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201008392B (en) | Treatment of pluripotent cells | |
IL217901A0 (en) | Treatment of bdnf-related disorders using laquninimod | |
IL211312A0 (en) | Treatment of stroke using isolated placental cells | |
IL217824A0 (en) | Treatment of of macrophage-related disorders | |
IL208354A0 (en) | Methods of treatment | |
GB0915515D0 (en) | Treatment of vasculoproliferative conditions | |
ZA201102604B (en) | Alkylcyclohexylethers of dihydrotetraazabenzoazulenes | |
HK1160925A1 (en) | Use of athepsin | |
GB0901456D0 (en) | Treatment of psoriasis | |
IL213607A0 (en) | 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases | |
GB0900599D0 (en) | Treatment | |
GB0801888D0 (en) | Treatment of mast cell related disorders | |
GB201013898D0 (en) | Well treatment | |
IL200753A0 (en) | Treatment of psoriasis | |
EP2240192A4 (en) | Treatment for dermatological conditions | |
GB0723100D0 (en) | Treatment of HFnEF | |
IL210558A0 (en) | Treatment of anxiety disorders | |
GB201001521D0 (en) | Treatment | |
GB0913968D0 (en) | Treatment | |
HK1157387A1 (en) | Use of hsa-producing cells | |
GB0819446D0 (en) | Treatment of inflammatory disorders | |
GB0809816D0 (en) | Treatment of ringworm | |
GB0808623D0 (en) | Treatment of keratinizing disorders | |
GB0816652D0 (en) | Cell therapy | |
GB0814322D0 (en) | Treatment of lysosomal storage disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |